

Abundance of Plasma Cells in a Case of Lipodermatosclerosis

Angel Fernandez-Flores¹, Jose A Manjón²

¹Service of Anatomic Pathology and the ²Service of Dermatology, Hospital El Bierzo;
¹Service of Cellular Pathology, Clinica Ponferrada, Ponferrada, Spain

Corresponding author:

Angel Fernandez-Flores, MD, PhD
S. Patología Celular, Clinica Ponferrada
Avenida Galicia 1
24400 Ponferrada
Spain
gpyauflowerlion@terra.es

Received: June 6, 2009

Accepted: December 18, 2009

SUMMARY Plasma cells have been considered as an important morphological clue in the diagnosis of some sclerosing cutaneous diseases such as morphea, so much so that humoral immunology has been suggested to have a role in the pathogenesis of such diseases. Nevertheless, they are hardly ever described as a prominent feature in lipodermatosclerosis in which granulocytes have been claimed as the main pathogenic cell. We report a case of lipodermatosclerosis in a 77-year-old woman, in which plasma cells were abundant in the thickened fibrous septa of the hypodermis. They were highlighted on immunohistochemical study with CD79a, CD138 and EMA, and showed polyclonal immunoreactivity of kappa and lambda immunoglobulin light chains.

KEY WORDS: lipodermatosclerosis, hypodermatitis sclerodermaformis, pseudoscleroderma, sclerosing panniculitis, plasma cells

INTRODUCTION

Plasma cells are a feature of many sclerosing cutaneous diseases, and they are considered as a clue in their diagnosis (1-8). Nevertheless, they are not claimed as a prominent feature in lipodermatosclerosis. In the latter condition, vascular stasis is many times a basic step in the development of the disease, but the role of leukocytes (mainly neutrophils) (9,10) has been claimed as princeps in its pathogenesis. This is in contrast with the role of humoral immunity claimed for other sclerosing diseases such as morphea.

Therefore, we consider it interesting to report a case of lipodermatosclerosis, in which plasma cells were a prominent feature. We want to note that such a clue need not necessarily favor the diagnosis of morphea over other sclerosing cutaneous diseases.

CASE REPORT

A 77-year-old woman presented for consultancy at Dermatology complaining of a lesion on her right leg, which she had noticed several months before. She had no other diseases.



Figure 1. Clinical picture showing erythematous lesion on the external side of the right leg.

The examination showed a reddish, indurated, slightly elevated area on her right leg (Fig. 1). Zones of vascular stasis were evident in both legs, with varicose lesions in both feet. A biopsy of the indurated area was performed.

Pathologic findings

Microscopic examination showed fibrosing dermatitis and panniculitis (Fig. 2). The upper part of the dermis showed a marked increase in the number of thick-wall vessels (Fig. 3, top left). Hypodermal septa were wide with thick bundles of collagen in them (Fig. 3, bottom left). Areas of lipomatous pseudomembranes were easily found (Fig. 3, top right), which stained with periodic acid of Schiff (PAS) (Fig. 3, bottom right). Iron deposits were mild in the dermis and abundant in the thickened septa of the hypodermis (Fig. 4). The inflammatory infiltrate of the septa was predominantly chronic, with a predominance of plasma cells (Fig. 5). The latter stood out with immunohistochemical stains for epithelial membrane antigen (EMA) (DakoCytomation, monoclonal mouse




Figure 2. Low power view of the biopsy specimen showing sclerosing dermatitis and panniculitis.

anti-human antibody, clone E29, code M0613), CD79a (DakoCytomation, monoclonal mouse anti-human antibody, clone JCB117, code M7050) and CD138 (DakoCytomation, monoclonal mouse anti-human antibody, clone MI15, code M7228) (Fig. 5). The immunohistochemical expression of kappa and lambda chains of immunoglobulins (DakoCytomation, monoclonal mouse anti-human kappa light chain, clone R10-21-F3, code N1568; and polyclonal rabbit anti-human lambda light chain, code N1513) showed a polyclonal pattern (Fig. 6).

None of the vascular structures expressed HHV-8 on immunohistochemical study (Novocastrol, clone 13B10).

The definitive diagnosis was lipodermatosclerosis.




Figure 3. Top left: fibrous dermatitis with dermal vascular changes typical of vascular stasis; bottom left: the hypodermis showing thickened fibrous septa; top right: lipomatous pseudomembranes were easily found. They were highlighted with PAS staining (bottom right).

DISCUSSION

Lipodermatosclerosis has been known in the literature under many other terms like hypodermatitis sclerodermaformis (11), pseudoscleroderma or sclerosing panniculitis (12). The latter is the preferred term by some authors (12), under the premise that it is actually a type of panniculitis (13).

The pathogenesis of the disease has not been fully understood, however, chronic venous insufficiency seems to play an important role (14-17). In fact, in a long series of patients with lipodermatosclerosis most of them presented venous abnormalities, of which deep vein incompetence was most common (present in nearly half of them)




Figure 4. Iron deposits were mild in the dermis, but prominent in the fibrous hypodermal septa.

(12). Even in patients with normal venous imaging studies, venous hypertension is mentioned as a possible factor in the disease development (12).

Among typical morphological features of the entity, most significant are thickening of the pannicular septa due to fibrosis, pseudomembrane formation, and mild inflammatory infiltrate. The role of inflammatory cells in lipodermatosclerosis has been widely described in many reports (18-21). Nevertheless, they are mostly centered on leukocytes other than plasma cells (22), mainly granulocytes (9,10). Plasma cells are mentioned




Figure 5. The inflammatory infiltrate of the fibrous septa was rich in plasma cells (top left). The plasma cell population expressed EMA (top right), CD79a (bottom left) and CD138 (bottom right).

as a component of the inflammatory infiltrate in fatal cases of venous insufficiency, under the edges of ulcerated lesions (23).

There is a theory known as “the white cell trapping” (24,25), stating that trapped leukocytes from the microcirculation release proteolytic enzymes (26). Leukocytes would get trapped due to several factors, e.g., prolonged standing, obesity, physical inactivity and genetic susceptibility (27). Leukocyte products would therefore be responsible for the endothelial damage, fibrin deposition and necrosis (28,29). The extravascular deposition of fibrin stimulates tissue fibrosis, which manifests as lipodermatosclerosis (30). This is worsened by the fact that the fibrinolytic activity of the blood and tissues is deficient in patients with lipodermatosclerosis (31). This is in contrast with the role of humoral immunity suggested in the development of other sclerosing diseases such as morphea, because of the evidence of abundant plasma cells in them (8).

It is interesting to mention that some authors distinguished an acute phase from the chronic one in lipodermatosclerosis (15). While venous insufficiency would be responsible for the acute




Figure 6. The immunohistochemical study for immunoglobulin light chains showed polyclonal expression of kappa (top) and lambda (bottom) chains.

phase, the chronic one would only develop as a post-phlebotic process. For some, only recurrent episodes of streptococcal cellulitis would lead to the sclerosing phase (32).

Even in morphological descriptions regarding lipodermatosclerosis, plasma cells are rarely mentioned as a main component of the inflammatory infiltrate. Some reports on lipodermatosclerosis mention that plasma cells are scattered (16,33). Nevertheless, they are not considered as frequent as in other sclerosing diseases such as morphea, scleromyxedema or eosinophilic fasciitis (34). In the latter sclerosing diseases, plasma cells are often a diagnostic clue (1-7,35). Linear scleroderma can even present as plasma cell panniculitis (36). Although some of these conditions can show marked vascular alterations (5), they are very different from those found in lipodermatosclerosis.

In conclusion, although plasma cells are traditionally considered as an outstanding feature in sclerosing diseases other than lipodermatosclerosis, we report a case with all the morphological clues typical of lipodermatosclerosis, in which such cells were abundant.

References

1. Fleischmajer R, Prunieras M. Cellular infiltrates in scleroderma skin. *Arch Dermatol* 1972;106:515-24.
2. Fleischmajer R, Jacotot AB, Shore S, Binnick SA. Scleroderma, eosinophilia, and diffuse fasciitis. *Arch Dermatol* 1978;114:1320-5.
3. Janin-Mercier A, Bourges M, Fonck-Cussac Y, Bussieres JL, Leblanc B, Delage J. Eosinophilic fasciitis. Ultrastructural study of an early biopsied case. *Virchows Arch A Pathol Anat Histol* 1981;394:177-84.
4. Gordon GV. Eosinophilic fasciitis. A case report and review of the literature. *Cutis* 1981;28:268, 271-3.
5. Kobayashi KA, Lui H, Prendiville JS. Solitary morphea profunda in a 5-year-old girl: case report and review of the literature. *Pediatr Dermatol* 1991;8:292-5.
6. Whittaker SJ, Smith NP, Jones RR. Solitary morphoea profunda. *Br J Dermatol* 1989;120:431-40.
7. Winkelmann RK, Connolly SM, Quimby SR, Griffing WL, Lie JT. Histopathologic features of the L-tryptophan-related eosinophilia-myalgia (fasciitis) syndrome. *Mayo Clin Proc* 1991;66:457-63.
8. Hamadah IR, Banka N. Autosomal recessive plasma cell panniculitis with morphea-like clinical manifestation. *J Am Acad Dermatol* 2006;54:S189-91.
9. Takase S, Schmid-Schönbein G, Bergan JJ. Leukocyte activation in patients with venous insufficiency. *J Vasc Surg* 1999;30:148-56.
10. Takase S, Lerond L, Bergan JJ, Schmid-Schönbein GW. The inflammatory reaction during venous hypertension in the rat. *Microcirculation* 2000;7:41-52.
11. Huriez C, Legache G, Desmons F, Pelce P. Ulcères de jambes et troubles trophiques d'un millier d'origine veineuse. *Rev Pract* 1955;5:2703-21.
12. Bruce AJ, Bennett DD, Lohse CM, Rooke TW, Davis MD. Lipodermatosclerosis: review of cases evaluated at Mayo Clinic. *J Am Acad Dermatol* 2002;46:187-92.
13. Jorizzo JL, White WL, Zanolli MD, Greer KE, Solomon AR, Jetton RL. Sclerosing panniculitis. A clinicopathologic assessment. *Arch Dermatol* 1991;127:554-8.
14. Falanga V, Bontempo FA, Eaglstein WH. Protein C and protein S plasma levels in patients with lipodermatosclerosis and venous ulceration. *Arch Dermatol* 1990;126:1195-7.
15. Kirsner RS, Pardes JB, Eaglstein WH, Falanga V. The clinical spectrum of lipodermatosclerosis. *J Am Acad Dermatol* 1993;28:623-7.
16. Naschitz JE, Yeshurun D, Schwartz H, Croitoru S, Shajrawi I, Misselevich I, *et al.* Pathogenesis of lipodermatosclerosis of venous disease: the lesson learned from eosinophilic fasciitis. *Cardiovasc Surg* 1993;1:524-9.
17. Myers KA, Ziegenbein RW, Zeng GH, Matthews PG. Duplex ultrasonography scanning for chronic venous disease: patterns of venous reflux. *J Vasc Surg* 1995;21:605-12.
18. Scott HJ, Coleridge Smith PD, Scurr JH. Histological study of white blood cells and their association with lipodermatosclerosis and venous ulceration. *Br J Surg* 1991;78:210-1.
19. Saharay M, Shields DA, Georgiannos SN, Porter JB, Scurr JH, Coleridge Smith PD. Endothelial activation in patients with chronic venous disease. *Eur J Vasc Endovasc Surg* 1998;15:342-9.
20. Peschen M, Grenz H, Brand-Saberi B, Bunaes M, Simon JC, Schopf E, *et al.* Increased expression of platelet-derived growth factor

- receptor alpha and beta and vascular endothelial growth factor in the skin of patients with chronic venous insufficiency. *Arch Dermatol Res* 1998;290:291-7.
21. Peschen M, Grenz H, Grothe C, Schöpf E, Vanscheidt W. Patterns of epidermal growth factor receptor, basic fibroblast growth factor and transforming growth factor-beta3 expression in skin with chronic venous insufficiency. *Eur J Dermatol* 1998;8:334-8.
 22. Phelps RG, Shoji T. Update on panniculitis. *Mt Sinai J Med* 2001;68:262-7.
 23. Markey AC, Tidman MJ, Rowe PH, Missen GA, Macdonald DM. Aggressive ulcerative necrobiosis lipoidica associated with venous insufficiency, giant-cell phlebitis and arteritis. *Clin Exp Dermatol* 1988;13:183-6.
 24. Coleridge Smith PD, Thomas P, Scurr JH, Dormandy JA. Causes of venous ulceration: a new hypothesis. *Br Med J (Clin Res Ed)* 1988;296:1726-7.
 25. Saharay M, Shields DA, Porter JB, Scurr JH, Coleridge Smith PD. Leukocyte activity in the microcirculation of the leg in patients with chronic venous disease. *J Vasc Surg* 1997;26:265-73.
 26. Zhang L, Zhang BG, Zhang JW, Zhang H. Immune function of erythrocytes in patients with chronic venous insufficiency of the lower extremities. *Chin Med J (Engl)* 2007;120:2224-8.
 27. Bergan JJ, Pascarella L, Schmid-Schönbein GW. Pathogenesis of primary chronic venous disease: insights from animal models of venous hypertension. *J Vasc Surg* 2008;47:183-92.
 28. Browse NL, Burnand KG. The cause of venous ulceration. *Lancet* 1982;2:243-5.
 29. Schmid-Schönbein GW, Takase S, Bergan JJ. New advances in the understanding of the pathophysiology of chronic venous insufficiency. *Angiology* 2001;52(Suppl 1):27-34.
 30. Burnand KG, Whimster I, Naidoo A, Browse NL. Pericapillary fibrin in the ulcer-bearing skin of the leg: the cause of lipodermatosclerosis and venous ulceration. *Br Med J (Clin Res Ed)* 1982;285:1071-2.
 31. Browse NL, Jarrett PE, Morland M, Burnand K. Treatment of liposclerosis of the leg by fibrinolytic enhancement: a preliminary report. *Br Med J* 1977;2:434-5.
 32. Fisher DA. Desideratum dermatologicum: eliminating lipodermatosclerosis; the term and the entities. *Int J Dermatol* 2000;39:490-2.
 33. Hazen PG, Carney JF, Engstrom CV, Turgeon KL, Reep MD, Tanphaichitr A. Lipomembranous panniculitis with ulceration and secondary calcinosis cutis: successful treatment using carbon dioxide laser Exci. *Wounds* 2006. Available at: <http://www.woundsresearch.com/article/5278> Last access: Feb 18, 2009.
 34. Baumgarten M, Gehr T, Mirovski M. Progressive skin fibrosis. *Am Fam Physician* 2008;78:505-7.
 35. Kobayasi T, Serup J. Vascular changes in morphea. *Acta Derm Venereol* 1985;65:116-20.
 36. Vincent F, Prokopetz R, Miller RA. Plasma cell panniculitis: a unique clinical and pathologic presentation of linear scleroderma. *J Am Acad Dermatol* 1989;21(2 Pt 2):357-60.